During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Uwe Platzbecker, University of Leipzig Medical Center, Leipzig, DE, about the highlights for patients with TP53-mutated AML from ASH 2020.
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Uwe Platzbecker, University of Leipzig Medical Center, Leipzig, DE, about the highlights for patients with TP53-mutated AML from ASH 2020.
ASH 2020: Highlights for patients with TP53-mutated AML
Platzbecker highlights the findings from a study evaluating the combination of azacitidine and magrolimab in patients with AML, including TP53-mutant AML.
Subscribe to get the best content related to AML delivered to your inbox